Cardiology,
Civil service commission,
Health,
Cardiovascular disease,
Pseudogene,
Cell,
Genetics,
Mental,
Abraxis BioScience,
Patient,
Female,
Cancer,
University,
Biology,
Biobank,
Epigenome,
Genomics,
European Commission,
Economics,
Medicine,
Pharmaceutical industry MENLO PARK, Calif., March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data. The announcement follows funding from the European Commission and the Estonian government to help Estonia adopt personalized medicine at scale and adapt public health systems to the biology of its population. The University will also support the European Union's 1+ Million Genomes initiative, which seeks to boost innovation in healthcare across Europe.
Key Points:
- The University will also support the European Union's 1+ Million Genomes initiative , which seeks to boost innovation in healthcare across Europe.
- 10,000 whole human genomes will be sequenced and analyzed by the Institute of Genomics at the University of Tartu using Revio.
- "The team chose PacBio HiFi technology over other long- and short-read offerings because of its ability to sequence complete and accurate genomes at competitive economics and scale.
- In addition to this 10,000-genome project, the Biobank team is looking to secure funding to sequence the entire biobank of over 200,000 samples to drive advances in health care globally.
The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Key Points:
- The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
- The Option has an exercise price of $3.67 per share, which is equal to the closing price of PacBio common stock on March 18, 2024 (the "Effective Date").
- The Option and the RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable award agreements thereunder entered into by the employee.
- Vesting of the shares subject to each of the Option and the RSUs is conditioned upon the employee's continued service through each applicable vesting date.
Gene,
Methylation,
FTD,
FMR1,
ALS,
Associate,
Myotonic dystrophy,
Abraxis BioScience,
Huntington's disease,
DNA,
Apple IIe,
Ataxia,
Laboratory,
University College London,
Frontotemporal dementia,
DSM-IV codes,
Mosaic,
High fidelity,
Instability MENLO PARK, Calif., March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The new long-read workflow can minimize iterative analysis using legacy technology, and reduce the time needed to identify disease-causing variants and associated methylation signatures.
Key Points:
- "This product uses a differentiated method to do targeted long-read sequencing of DNA in its pure state.
- Continuing the commitment to deliver comprehensive solutions, PacBio has prioritized delivering end-to-end workflows with their latest products.
- The PureTarget Repeat Expansion Panel workflow utilizes the recently announced Nanobind PanDNA kit , ensuring robust results optimized for Revio and Sequel IIe users.
- Customers can multiplex up to 48 samples on the PacBio Revio sequencing system and 24 samples on the PacBio Sequel IIe sequencing system.
MENLO PARK, Calif., Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
Key Points:
- MENLO PARK, Calif., Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 PM ET in Boston, MA
Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 10:15 AM ET in Miami Beach, FL
Live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com.
- Webcast replays will be available for at least 30 days following the event.
Social media,
Biotechnology,
Kinect,
ROI,
Marketing,
Grammy Awards,
The Minority Report,
NOVO,
Lightning,
Maroon 5,
Creativity,
AEG,
Movement,
Minority,
Microsoft,
Entertainment ATLANTA, Feb. 13, 2024 /PRNewswire/ -- VOLO Events Agency (VOLO), a leading producer of experiential marketing and live events for global brands, has won the best Event Technology award at the BizBash 11th Annual Event Experience Awards.
Key Points:
- ATLANTA, Feb. 13, 2024 /PRNewswire/ -- VOLO Events Agency (VOLO), a leading producer of experiential marketing and live events for global brands, has won the best Event Technology award at the BizBash 11th Annual Event Experience Awards.
- The award recognizes the outstanding use of technology to create an immersive and engaging event experience for PacBio ( NASDAQ: PACB ) a pioneering leader in the Biotechnology industry.
- Far from traditional formats, this avant-garde theatrical technology sensitized the audience, creating a vulnerable ground, delivering an impressive launch event .
- I couldn't be prouder of our work and team, who delivered an exceptional product launch event for PacBio and their customers.
MENLO PARK, Calif., Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system. With these kits, PacBio takes another leap forward in the long-read market by offering customers automated, scalable, and high-performance library preparation solutions with a 40 percent reduction in costs and a 60 percent decrease in workflow time. In addition, with the HiFi Plex Prep Kit 96 now including 384 validated barcode adapters, customers will have the groundbreaking ability to run 1,536 samples in a single Revio run.
Key Points:
- In addition, with the HiFi Plex Prep Kit 96 now including 384 validated barcode adapters, customers will have the groundbreaking ability to run 1,536 samples in a single Revio run.
- We are thrilled with the prospect of providing customers with meaningful options for scale that allow them to explore emerging applications."
- Engineered for efficiency, the new HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 are designed to allow users the ability to automate long-read sequencing workflow steps and streamline the process of preparing, pooling, and loading samples.
- "The speed and ease of use of the HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 has made it possible for us to use long-read sequencing as a high-throughput genotyping tool."
MENLO PARK, Calif., Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024, at 5:00 pm Eastern Time.
Key Points:
- MENLO PARK, Calif., Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024, at 5:00 pm Eastern Time.
- The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ .
- Listen live via internet or replay: https://investor.pacificbiosciences.com/
If using the dial-in option, please dial into the call ten minutes prior to start time using the appropriate number above and ask to join the "PacBio Q4 Earnings Call."
Research,
Animal,
DNA,
CBB,
Atomic mass,
Tree,
Compatibility,
Abraxis BioScience,
Cell,
Bacteria,
High fidelity,
Medical research,
Plant,
Fungus,
Wellcome Sanger Institute,
Blood MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects.
Key Points:
- MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit.
- Nanobind kits are designed for researchers to efficiently extract high-quality, high molecular weight DNA across a wide range of sample types.
- These kits are versatile, accommodating both manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT kit) settings.
- "The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing," said Jeff Eidel, Chief Commercial Officer at PacBio.
RNA,
Conference,
Apple IIe,
High fidelity,
Economics,
Elasticity,
DNA,
Abraxis BioScience,
Genetics,
SMRT,
Genomics,
University,
Event,
Ship,
Genome,
Growth,
Investment,
Video game MENLO PARK, Calif., Jan. 8, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter 2023 and full year 2023 of $58.4 million and $200.5 million representing year-over-year growth of 113% and 56%, respectively.
Key Points:
- PacBio reported preliminary, unaudited revenue of approximately $58.4 million for its fourth quarter ended December 31, 2023.
- Preliminary instrument revenue for the fourth quarter of 2023 is expected to be approximately $35.1 million, compared with $6.1 million for the fourth quarter of 2022.
- Preliminary consumables revenue for the fourth quarter of 2023 is expected to be approximately $18.9 million, compared with $16.7 million for the fourth quarter of 2022.
- Preliminary service and other revenue for the fourth quarter of 2023 is expected to be approximately $4.4 million, compared with $4.6 million for the fourth quarter of 2022.
MENLO PARK, Calif., Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 1:30 PM PT (4:30 PM ET) in San Francisco, California.
Key Points:
- MENLO PARK, Calif., Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 1:30 PM PT (4:30 PM ET) in San Francisco, California.
- A live webcast of the event can be accessed at the company's investors page at investor.pacificbiosciences.com.
- A replay of the webcast will be available for at least 30 days following the event.
